Stay updated with breaking news from Vasanthi Viswanathan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kojin Therapeutics likes to do things differently: Its platform is looking to—for the first time—drug the ferroptosis-sensitive cell state and treat a host of diseases, and, now, an all-woman leadership team will help make that happen.
Kojin Therapeutics has raised $60 million to use iron-dependent cell death to treat drug-resistant cancer. The series A round positions the biotech to build on the work its scientific founders did at institutions including Harvard University and Dana-Farber Cancer Institute.
Published: Jun 09, 2021 By Mark Terry Kojin Therapeutics launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices. The approach came out of the laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benj...